about
Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlothoFibroblast growth factor 21: from pharmacology to physiologyFibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan CrosstalkSignificant roles of anti-aging protein klotho and fibroblast growth factor23 in cardiovascular diseaseFibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsRegulation and function of the FGF23/klotho endocrine pathwaysMetabolic hormone FGF21 is induced in ground squirrels during hibernation but its overexpression is not sufficient to cause torporFrom "Kidneys Govern Bones" to Chronic Kidney Disease, Diabetes Mellitus, and Metabolic Bone Disorder: A Crosstalk between Traditional Chinese Medicine and Modern ScienceCirculating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in ChineseCharacterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolismThe Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.Therapeutic utilities of fibroblast growth factor 19.FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profileRole of angiopoietin-2 in the cardioprotective effect of fibroblast growth factor 21 on ischemia/reperfusion-induced injury in H9c2 cardiomyocytes.Liver zonation: Novel aspects of its regulation and its impact on homeostasis.The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract.FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-Klotho bispecific protein.Involvement of SOX-9 and FGF-23 in RUNX-2 regulation in osteoarthritic chondrocytesMinireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic DiseasesLow body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23.Serum fibroblast growth factor 19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels.Increased susceptibility to diet-induced gallstones in liver fatty acid binding protein knockout mice.Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue.The 2008 Pittendrigh/Aschoff lecture: peripheral phase coordination in the mammalian circadian timing system.FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre studyVitamin D in liver diseases: from mechanisms to clinical trials.Trans-system mechanisms against ischemic myocardial injury.Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis.Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.The relationship of fibroblast growth factors 21 and 23 and α-Klotho with platelet activity measured by platelet volume indices.WNK4 is an essential effector of anterior formation in FGF signaling.Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis.Short-term dietary phosphate restriction up-regulates ileal fibroblast growth factor 15 gene expression in mice.Temporal and spatial expression of FGF ligands and receptors during Xenopus development.Fibroblast growth factor 19 entry into brain.Cynomolgus monkey gallbladder bile contains high concentrations of fibroblast growth factor 19.Downregulation of klotho β is associated with invasive ductal carcinoma progression.Increased glucose-stimulated FGF21 response to oral glucose in obese nondiabetic subjects after Roux-en-Y gastric bypass.Reduced ileal expression of OSTalpha-OSTbeta in non-obese gallstone disease.
P2860
Q24306135-0189E7E5-508A-4CB9-A7D7-B5116CA0A2CAQ24658126-DC2F62A5-C993-4037-8730-0678286285D5Q26766528-162A7997-1589-4684-B998-ACC313E752B7Q26782946-2F31B7EC-ADFA-4596-BB0C-68443DC808E4Q26801718-C1009A01-D097-489D-96F5-D5D2CA757CB9Q26860470-8733BB9A-CE0F-4A82-9DDE-1B4495D8C061Q27321257-B6439B12-D0B0-48C5-84B5-F0F659FFD7E4Q28079011-036AA302-31E9-4413-B333-6830914FBB9CQ28477784-C03BDC25-2673-4AD7-8E6B-A34957362B40Q28730955-0BE8939C-CE2C-4BE4-8E41-3578CDE6433AQ30234616-0585ACE0-14A9-44B7-A3AD-7EA15DF5B37FQ30407643-EF9CDD94-6230-42D0-A335-C1D94DC42D23Q33648263-112E342C-429C-4792-8E44-A9B2119738E6Q33785827-FEA3E20B-F958-4481-A9BA-0D1F089279FDQ33847421-6FD8DD4B-A578-4F1D-B9B0-05C4E82E7C15Q33886995-09ABFBEA-7406-4374-869E-550D56189A73Q34219880-8F31C938-4729-466E-AC24-8BA2864C3D2BQ34695496-453E16D9-5B26-40CF-B39A-3C36564170B0Q35893262-21A80B28-7B1B-41F7-91C3-A8C0370C6198Q36107291-18ACBC17-E125-4B70-B686-CB0ED84608FEQ37029683-AA099460-EE3B-4E89-B38F-4BAF36FCE4F1Q37106431-60B6CE5E-0005-43D7-8BC3-1937B8268DB1Q37151863-F6D14A6D-E20D-43C8-AC2E-804F954C4C69Q37199307-2FFF380F-D42C-4F97-972A-FAB514ED399AQ37371302-9F41D695-25BC-4BB3-BF74-184947C1AD7EQ37594375-373C4F99-4852-4922-A819-C660E70E0678Q38121572-1876E9FC-183D-47B2-A797-A2D5AF54F5D9Q38318626-16B305ED-6D3D-49A3-8383-7D4118B473CBQ38723818-1AE4208F-817F-4CE4-8E22-38C0840B81C5Q38794405-0CFF8B52-D71D-4BDB-9620-C1091DF8A4D1Q39028213-0DBC1E0B-E77C-4FE4-B637-72BFB3A3FB99Q41781994-172909E3-7E5C-4DA5-863B-1D661BDD32A0Q41974026-35802872-A77A-4D69-B5A1-9631414BD2EEQ42416047-8E965CBB-EF2C-4E71-9EE5-EFC3E4F55FD5Q42545128-1B01EF4C-3EBF-4C2E-AE23-1F6164B2A143Q42920547-F2359A11-F3D6-4818-A3A9-67EE0232F2BFQ45222692-1916FC74-DD6C-46E5-A230-FC00786F1172Q49298283-EC683C92-A8CA-49A9-9666-492A1E9E18FFQ51278940-1D29C75A-8256-4878-B821-37E0F4F199C0Q51702927-E8882353-AA4D-4B5E-9F85-A6AB62A6EED6
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Actions and mode of actions of FGF19 subfamily members
@ast
Actions and mode of actions of FGF19 subfamily members
@en
Actions and mode of actions of FGF19 subfamily members
@nl
type
label
Actions and mode of actions of FGF19 subfamily members
@ast
Actions and mode of actions of FGF19 subfamily members
@en
Actions and mode of actions of FGF19 subfamily members
@nl
prefLabel
Actions and mode of actions of FGF19 subfamily members
@ast
Actions and mode of actions of FGF19 subfamily members
@en
Actions and mode of actions of FGF19 subfamily members
@nl
P3181
P1433
P1476
Actions and mode of actions of FGF19 subfamily members
@en
P2093
Seiji Fukumoto
P3181
P356
10.1507/ENDOCRJ.KR07E-002
P407
P577
2008-03-01T00:00:00Z